News | July 24, 2021
Lonza reports strong momentum in H1 2021
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
Sun Pharma has committed Rs. 100 crores towards these initiatives
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Subscribe To Our Newsletter & Stay Updated
